Your browser doesn't support javascript.
loading
Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Charokopou, M; Vioix, H; Verheggen, B; Eddowes, L A; Griffiths, M; Gabriel, Z; Tolley, K; Franks, D.
Affiliation
  • Charokopou M; Pharmerit International, Rotterdam, The Netherlands.
  • Vioix H; AstraZeneca UK Ltd., Luton, UK.
  • Verheggen B; Pharmerit International, Rotterdam, The Netherlands.
  • Eddowes LA; Costello Medical Consulting Ltd., Cambridge, UK.
  • Griffiths M; Costello Medical Consulting Ltd., Cambridge, UK.
  • Gabriel Z; AstraZeneca UK Ltd., Luton, UK.
  • Tolley K; Tolley Health Economics Ltd., Buxton, Derbyshire, UK.
  • Franks D; AstraZeneca UK Ltd., Luton, UK.
Value Health ; 17(7): A347, 2014 Nov.
Article in En | MEDLINE | ID: mdl-27200659
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Evaluation_studies / Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Países Bajos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Evaluation_studies / Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Países Bajos